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Abstract
Introduction: Breast cancer in men is rare. The evidence about treatment has been derived from
data on the management of the disease in women. The usual treatment is for male patients to
undergo modified radical mastectomy. There is insufficient experience of breast conserving surgery
with preservation of the nipple. The management of patients who demand such an approach for
personal reasons remains a challenge for both the surgeon and oncologist.
Case presentation: A 50-year-old man with a breast cancer was successfully managed with
breast conserving surgery with nipple preservation combined with axillary clearance and
postoperative radiotherapy, chemotherapy and hormone treatment. Since there are no similar
cases in the literature, we discuss the feasibility, safety and possible indications of such an approach.
Conclusion: Despite the limited indications and evidence about the safety and efficacy of breast
conserving surgery with nipple preservation in men with breast cancer, it is a feasible approach if
other options are declined by the patient. More studies are necessary to reach firm conclusions
about the safety of such an approach.
Introduction
Male breast cancer (MBC) is a rare disease and accounts
for less than 1% of breast cancers but incidence seems to
be increasing [1-6]. Owing to the small number of cases,
management of MBC is based on evidence derived from
data analysis of female breast cancer (FBC) patients and
on retrospective studies of a limited number of MBC
patients [2,3,5]. There is little experience of breast con-
serving surgery (BCS) with nipple preservation, as usually
there is no interest for the treatment from either the sur-
geon or patient. Therefore, management of those patients
who demand such an approach remains a challenge for
the treating physicians.
Case presentation
A 50-year-old man was referred to the breast unit present-
ing with a month's history of a suspicious lump in his left
breast. He had no family history of cancer. From his med-
ical history, the only remarkable finding was hepatitis B
30 years previously and genital herpes for which he was
taking Acyclovir. He had a history of smoking (30 packs
per year).
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Clinically, he had a lump centrally in the left breast, at a 6
o'clock position, with skin tethering and mild inversion of
the nipple. Ultrasound (US) and a mammogram demon-
strated a 1 cm suspicious lesion, which was found to be
cancer on both fine needle aspiration (FNA) and core
biopsy. The tumour was a grade 2 invasive ductal carci-
noma (IDC). Investigations did not show any distant
metastases. The patient was offered modified radical mas-
tectomy and sentinel node biopsy (SNB). The patient
declined any operation that would not preserve the nipple
and insisted on having BCS. After discussion with the
oncologists and patient about the risk of recurrence, we
proceeded with BCS with nipple preservation and SNB.
The sentinel node was involved and level III axillary clear-
ance was performed. Overall, one out of nine dissected
lymph nodes was positive. Our well-established protocols
for wide local excisions rely on 5 mm pathological clear
margins rather than negative margins [7]. Therefore, we
do not use frozen sections to assess the surgical margins.
The specimen weighed 19 g and included a 0.7 × 0.7 × 1
cm grade 2 IDC with an intermediate grade ductal carci-
noma in situ (DCIS), comprising 5% of the tumour mass.
The tumour was positive for oestrogen (ER) and proges-
terone receptors (PgR). The DCIS was present 0.2 cm from
the superficial margin and all other margins were more
than 0.8 cm.
The patient had four cycles of chemotherapy (Doxoru-
bicin 100 mg and Cyclophosphamide 1000 mg) and
adjuvant chest wall radiotherapy (50 gray in 25 fractions),
which he tolerated well. He was commenced on
Tamoxifen 20 mg once a day for 5 years and then switched
to Letrozole 2.5 mg. Repeated followup clinical examina-
tions, mammograms, breast US, bone scans and liver US
showed no evidence of disease. Eight years after the oper-
ation, the mammogram showed microcalcifications in the
ipsilateral breast and he underwent diagnostic biopsy of
the area, which showed fibrofatty tissue with focal stromal
calcifications without features of malignancy.
Discussion
MBC behaves in a way similar to FBC in postmenopausal
women [6]. Unlike FBC, there is only one peak at 67–71
years of age [2,4,6]. Family history, genetic factors (for
example, BRCA gene carriers, AR and CYP17 gene muta-
tion, Klinefelter syndrome, Cowden syndrome), exoge-
nous oestrogen administration and testicular anomalies
are among the risk factors [1-4,6], while radiation, obesity
and alcohol use are proposed but not widely accepted as
risk factors [2,3,6]. There is no proven association
between gynaecomastia and MBC [4,6]. Histologically,
more than 85% of tumours are of the invasive ductal type
[4,6]. Furthermore, over 90% of MBC express ER while
81% express PgR [5,8]. C-erb-B2 is less likely to be
expressed (about 5%) [2,3]. In men, 20% of the circulat-
ing estrogen is produced by the testis while about 80%
results from peripheral aromatisation of androgens [3,9].
The usual presentation is a palpable painless lump with or
without skin changes or nipple involvement but often
diagnosis is delayed [4,6]. The sensitivity of the mammo-
gram is reported to be 92% while specificity is 90% [6].
Breast US can be used to evaluate the tumour in the same
way as in women [2,4,10]. The prognosis depends on
tumour size, grade and extent of lymph node involvement
in the same way as in FBC [2,6]. Overall survival rate when
corrected for age is similar to that of FBC [2,6].
Traditionally patients with MBC undergo modified radi-
cal mastectomy with either SNB or axillary node clearance
(ANC) [2,3,6]. Despite the lack of firm evidence about the
safety of SNB, increasingly there is an acceptance of the
technique and its use [2,6]. Radiation therapy seems to
prevent local recurrence but it is not known whether it
adds anything to survival. The indications and dose
remain the same as in women [2,6]. Ablative techniques
aiming to control hormones, including orchidectomy,
adrenalectomy and hypophysectomy, have been used in
the past but had severe side effects, therefore medical hor-
mone manipulation has been tried [3,5]. For those
patients with hormone receptor-positive tumours, there is
a clear benefit from the use of Tamoxifen in both disease-
free and overall survival [3,5,6,11,12]. There is also a
proven effectiveness in those patients with metastatic dis-
ease and, therefore, Tamoxifen has been incorporated in
the treatment of MBC [2,3,5,11]. There is not sufficient
evidence for the use of aromatase inhibitors despite the
advances and proven efficacy in FBC and more studies
need to be done [2,3,5]. There are case reports supporting
a good response to Letrozole [3,13] even after failure of
Tamoxifen [3]. There is also some evidence about the
effectiveness of adjuvant chemotherapy. One prospective
study with a small number of patients (N = 24) showed a
survival benefit and other studies support this finding
[14]. Moreover, retrospective studies show reduction of
the risk of local recurrence [2,6,15].
Conclusion
Despite limited indications and lack of evidence about the
safety and efficacy of BCS with nipple preservation in men
with breast cancer, it is a feasible approach if other
options are declined by the patient. Apparently obtaining
good excision margins is the most important predictor of
local recurrences as it is for women.
With a case report of only one patient, it is impossible to
make any statement about the safety of such an approach
and more studies are necessary to reach firm conclusions.Publish with BioMed Central    and   every 
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